Expert Interview
Discussing the SKYSCRAPER-01 trial of tiragolumab in Non Small Cell Lung Cancer (NSCLC) and readthrough to iTeos/GSK's belrestotug
Ticker(s): ITOS, GSK, RHHBYInstitution: Cleveland Clinic
- Vice Chair of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Center.
- Thoracic medical oncologist with over 20 years of clinical experience; Active clinical investigator in trials involving NSCLC and small cell lung cancer as well as mesothelioma.
- Treats 20-25 new NSCLC patients per month and currently manages over 200 active patients with NSCLC.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
